Abdouh Mohamed, Hamam Dana, Arena Vincenzo, Arena Manuel, Alamri Hussam, Arena Goffredo Orazio
Cancer Research Program, McGill University Health Centre-Research Institute, Montreal, Quebec, Canada.
Department of Experimental Surgery, Faculty of Medicine, McGill University, Montreal, Quebec, Canada.
J Circ Biomark. 2016 Nov 4;5:1849454416663661. doi: 10.1177/1849454416663661. eCollection 2016 Jan-Dec.
We reported that single oncosuppressor-mutated (SOM) cells turn malignant when exposed to cancer patients' sera. We tested the possibility to incorporate this discovery into a biological platform able to detect cancer in healthy individuals and to predict metastases after tumor resection. Blood was drawn prior to tumor resection and within a year after surgery. Blood samples from healthy individuals or metastatic patients were used as negative and positive controls, respectively. Patients at risk for cancer were included in the screening cohort. Once treated, cells were injected into nonobese diabetic/severe combined immunodeficiency mice to monitor tumor growth. All samples of sera coming from metastatic patients transformed SOM cells into malignant cells. Four samples from screened patients transformed SOM cells. Further clinical tests done on these patients showed the presence of early cancerous lesions despite normal tumor markers. Based on the xenotransplants size, we were able to predict metastasis in three patients before diagnostic tests confirmed the presence of the metastatic lesions. These data show that this serum-based platform has potentials to be used for cancer screening and for identification of patients at risks to develop metastases regardless of the Tumor Node Metastasis (TNM) stage or tumor markers level.
我们报告称，单个肿瘤抑制基因突变（SOM）细胞在接触癌症患者血清时会发生恶变。我们测试了将这一发现纳入一个生物平台的可能性，该平台能够在健康个体中检测癌症，并在肿瘤切除后预测转移情况。在肿瘤切除前和手术后一年内采集血液。分别将健康个体或转移性患者的血样用作阴性和阳性对照。有癌症风险的患者被纳入筛查队列。细胞经处理后，注射到非肥胖糖尿病/严重联合免疫缺陷小鼠体内以监测肿瘤生长。所有来自转移性患者的血清样本都将SOM细胞转化为了恶性细胞。来自筛查患者的四个样本也将SOM细胞转化了。对这些患者进行的进一步临床检测显示，尽管肿瘤标志物正常，但仍存在早期癌性病变。根据异种移植的大小，我们能够在诊断测试确认转移病灶存在之前，预测出三名患者会发生转移。这些数据表明，这个基于血清的平台有潜力用于癌症筛查，以及识别有发生转移风险的患者，而不论肿瘤淋巴结转移（TNM）分期或肿瘤标志物水平如何。
